Spinal Muscular Atrophy Sma Epidemiology Forecast

DelveInsight's 'Spinal Muscular Atrophy (SMA) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Spinal Muscular Atrophy (SMA) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Spinal Muscular Atrophy (SMA) Understanding

The DelveInsight Spinal Muscular Atrophy (SMA) epidemiology report gives a thorough understanding of the Spinal Muscular Atrophy (SMA) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Spinal Muscular Atrophy (SMA) in the US, Europe, and Japan. The report covers the detailed information of the Spinal Muscular Atrophy (SMA) epidemiology scenario in seven major countries (US, EU5, and Japan).


Spinal Muscular Atrophy (SMA) Epidemiology Perspective by DelveInsight

The Spinal Muscular Atrophy (SMA) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Spinal Muscular Atrophy (SMA) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Spinal Muscular Atrophy (SMA) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Spinal Muscular Atrophy (SMA) Detailed Epidemiology Segmentation

The Spinal Muscular Atrophy (SMA) epidemiology covered in the report provides historical as well as forecasted Spinal Muscular Atrophy (SMA) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Spinal Muscular Atrophy (SMA) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Spinal Muscular Atrophy (SMA) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Spinal Muscular Atrophy (SMA) Epidemiology Report and Model provide an overview of the risk factors and global trends of Spinal Muscular Atrophy (SMA) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Spinal Muscular Atrophy (SMA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Spinal Muscular Atrophy (SMA)
  • The report provides the segmentation of the Spinal Muscular Atrophy (SMA) epidemiology


Report Highlights

  • 11-Year Forecast of Spinal Muscular Atrophy (SMA) epidemiology
  • 7MM Coverage
  • Total Cases of Spinal Muscular Atrophy (SMA)
  • Total Cases of Spinal Muscular Atrophy (SMA) according to segmentation
  • Diagnosed cases of Spinal Muscular Atrophy (SMA)


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Spinal Muscular Atrophy (SMA)?
  • What are the key findings pertaining to the Spinal Muscular Atrophy (SMA) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Spinal Muscular Atrophy (SMA) across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Spinal Muscular Atrophy (SMA)?
  • What are the currently available treatments of Spinal Muscular Atrophy (SMA)?


Reasons to buy

  • The Spinal Muscular Atrophy (SMA) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Spinal Muscular Atrophy (SMA) market
  • Quantify patient populations in the global Spinal Muscular Atrophy (SMA) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Spinal Muscular Atrophy (SMA) therapeutics in each of the markets covered
  • Understand the magnitude of Spinal Muscular Atrophy (SMA) population by its epidemiology
  • The Spinal Muscular Atrophy (SMA) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Spinal Muscular Atrophy (SMA)

3. Spinal Muscular Atrophy (SMA): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Spinal Muscular Atrophy (SMA) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Spinal Muscular Atrophy (SMA) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Spinal Muscular Atrophy (SMA) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Spinal Muscular Atrophy (SMA) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Spinal Muscular Atrophy (SMA) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Spinal Muscular Atrophy (SMA) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Spinal Muscular Atrophy (SMA) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Spinal Muscular Atrophy (SMA) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Spinal Muscular Atrophy (SMA) Treatment and Management

6.2. Spinal Muscular Atrophy (SMA) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Spinal Muscular Atrophy (SMA) Epidemiology in 7MM (2017-2030)

Table 2 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Spinal Muscular Atrophy (SMA) Epidemiology in the United States (2017-2030)

Table 4 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Spinal Muscular Atrophy (SMA) Epidemiology in Germany (2017-2030)

Table 6 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Spinal Muscular Atrophy (SMA) Epidemiology in France (2017-2030)

Table 8 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Spinal Muscular Atrophy (SMA) Epidemiology in Italy (2017-2030)

Table 10 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Spinal Muscular Atrophy (SMA) Epidemiology in Spain (2017-2030)

Table 12 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Spinal Muscular Atrophy (SMA) Epidemiology in the United Kingdom (2017-2030)

Table 14 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Spinal Muscular Atrophy (SMA) Epidemiology in Japan (2017-2030)

Table 16 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Spinal Muscular Atrophy (SMA) Epidemiology in 7MM (2017-2030)

Figure 2 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Spinal Muscular Atrophy (SMA) Epidemiology in the United States (2017-2030)

Figure 4 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Spinal Muscular Atrophy (SMA) Epidemiology in Germany (2017-2030)

Figure 6 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Spinal Muscular Atrophy (SMA) Epidemiology in France (2017-2030)

Figure 8 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Spinal Muscular Atrophy (SMA) Epidemiology in Italy (2017-2030)

Figure 10 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Spinal Muscular Atrophy (SMA) Epidemiology in Spain (2017-2030)

Figure 12 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Spinal Muscular Atrophy (SMA) Epidemiology in the United Kingdom (2017-2030)

Figure 14 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Spinal Muscular Atrophy (SMA) Epidemiology in Japan (2017-2030)

Figure 16 Spinal Muscular Atrophy (SMA) Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Spinal Muscular Atrophy (SMA) Epide...
  • Spinal Muscular Atrophy (SMA)
  • Spinal Muscular Atrophy (SMA) Pipe...
  • Spinal Muscular Atrophy (SMA) Comp...
  • Spinal Muscular Atrophy (SMA) prev...
  • Spinal Muscular Atrophy (SMA) inci...
  • Spinal Muscular Atrophy (SMA) pati...
  • Spinal Muscular Atrophy (SMA) trea...

Forward to Friend

Need A Quote